Fixed-Combination Hypertension Drugs Get Clearer Regulatory Pathway, But Will Pharma Follow?
Executive Summary
Significant effects are expected to be observed on both systolic and diastolic blood pressures, US FDA final guidance says in lone substantive change from January draft aimed at streamlining development for multi-drug combinations of previously approved products; with only five such products in the clinical pipeline according to Biomedtracker data, there appears to be little big pharma interest in this space.